revumenib
syndax pharma
['revumenib', 'leusm', 'augment,trial', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'augment,data', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'augment-101', 'augment,study', 'leukemia', 'sndx-5613', 'kura ']
congress | #ash22 delivers an update on the phase i part of the augment-101 trial. patients with r/r kmt2ar or mnpm1 acute leukemia who received sndx-5613 and proceeded to transplant experienced durable remissions. #amlsm #leusm 
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm